Food & Drug Allergy
14 cases on peanut and multi-food oral immunotherapy, early peanut introduction and the NIAID addendum, sustained-unresponsiveness testing, cross-reactive pollen-food syndrome, alpha-gal syndrome and cetuximab cross-reactivity, FPIES resolution testing, penicillin allergy delabeling, unverified perioperative drug-allergy labels, severe cutaneous drug reactions and anticonvulsant cross-reactivity, radiocontrast premedication versus agent switching, aspirin/NSAID desensitization after PCI, epinephrine route selection, and biphasic-reaction prevention — choose a case below to open its full multi-voice debate.
A boy's rising peanut-specific IgE and a recent anaphylaxis test whether oral immunotherapy or continued avoidance is the safer path forward.
A teenager with three food allergies and a family that already ruled out running three separate immunotherapy schedules considers a newly approved biologic instead.
A 5-month-old's severe eczema and an older sibling's near-fatal peanut allergy set guideline-recommended testing against how long an allergy referral actually takes.
A teenager who has never had a reaction on maintenance dosing raises the question of stopping — but the trial that actually tested discontinuation found most patients don't stay protected.
Fifteen years of mild oral itching and one systemic reaction leave a woman's cross-reactive food list split between what her component testing clears and what it can't.
A tick-bite-acquired red meat allergy runs directly into a chemotherapy antibody that carries the same carbohydrate the patient is already sensitized to.
A toddler's undetectable milk-specific IgE makes her a favorable candidate for a resolution challenge — but her family's fear and her narrowing diet are pulling the timeline in opposite directions.
A validated risk score and a rising creatinine push a hospitalized man's decades-old penicillin label toward a same-day oral challenge instead of the traditional skin-test-first pathway.
One patient has six weeks to sort out three unverified allergy labels before surgery; another has hours, a documented severe reaction, and no time left to test anything.
A DRESS reaction to carbamazepine has left a man's seizures poorly controlled — and every anticonvulsant that would work best for his seizure type shares a chemical family with the drug that nearly killed him.
A moderate contrast reaction five years ago meets a new lymphoma diagnosis that needs contrast-enhanced imaging now — and premedication and agent selection turn out not to answer the same question.
A man with a new drug-eluting stent needs guideline-standard dual antiplatelet therapy — but his history of NSAID-induced hives puts aspirin itself in question, and a newer trial complicates what the alternative even is.
Two anaphylactic reactions were delayed by minutes that mattered — not by lack of medication, but by a needle fear no amount of training has fixed.
Standard practice has long added a steroid before discharge after anaphylaxis — but the evidence behind it, and the drug's own timing, don't line up the way the practice assumes.